{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:27:04Z","timestamp":1784305624572,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clinthera.2023.12.007","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:14:14Z","timestamp":1706832854000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs"],"prefix":"10.1016","volume":"46","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Darling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Lukacova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.12.007_bib0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0002","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1073\/pnas.0812394106","article-title":"Partial reversal of Rett syndrome\u2013like symptoms in MeCP2 mutant mice","volume":"106","author":"Tropea","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0003","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","article-title":"NNZ-2566: a Gly\u2013Pro\u2013Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke","volume":"278","author":"Bickerdike","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/neu.2008.0629","article-title":"NNZ-2566, a glypromate analogue, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury","volume":"26","author":"Lu","year":"2009","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0005","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/jcbfm.2009.109","article-title":"NNZ-2566, a glypromate analogue, attenuates brain ischemia-induced non-convulsive seizures in rats","volume":"29","author":"Lu","year":"2009","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-6-19","article-title":"NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats","volume":"6","author":"Wei","year":"2009","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0007","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0008","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0009","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ajmg.a.38191","article-title":"Evaluation of QTc in Rett syndrome: correlation with age, severity, and genotype","volume":"173","author":"Crosson","year":"2017","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2017.01.032","article-title":"Scoliosis in Rett syndrome: progression, comorbidities, and predictors","volume":"70","author":"Killian","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0011","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.braindev.2012.11.007","article-title":"Pubertal trajectory in females with Rett syndrome: a population-based study","volume":"35","author":"Knight","year":"2013","journal-title":"Brain Dev"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0012","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1203\/PDR.0b013e318180ebcd","article-title":"Bone mineral content and bone mineral density are lower in older than in younger females with Rett syndrome","volume":"64","author":"Motil","year":"2008","journal-title":"Pediatr Res"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","article-title":"Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome","volume":"55","author":"Motil","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.braindev.2018.08.008","article-title":"Behavioral profiles in Rett syndrome: data from the natural history study","volume":"41","author":"Buchanan","year":"2019","journal-title":"Brain Dev"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0015","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1212\/WNL.0b013e3182377dd2","article-title":"Clinical severity and quality of life in children and adolescents with Rett syndrome","volume":"77","author":"Lane","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0016","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/brain\/aww302","article-title":"Longitudinal course of epilepsy in Rett syndrome and related disorders","volume":"140","author":"Tarquinio","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug\u2013drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0018","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0019","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions\u2014principles and clinical implications","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008571-199410000-00003","article-title":"CYP3A gene expression in human gut epithelium","volume":"4","author":"Kolars","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0021","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \"pie\"","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fgene.2013.00012","article-title":"Pharmacogenomics of cytochrome P450 3A4: recent progress toward the \"missing heritability\" problem","volume":"4","author":"Klein","year":"2013","journal-title":"Front Genet"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0300-483X(95)03155-9","article-title":"Substrates of human hepatic cytochrome P450 3A4","volume":"104","author":"Li","year":"1995","journal-title":"Toxicology"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0024","unstructured":"US Food and Drug Administration. Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers [FDA website]. Available at: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed October 22, 2021."},{"key":"10.1016\/j.clinthera.2023.12.007_bib0025","unstructured":"US Food and Drug Administration. Clinical Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry [FDA website]. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Accessed October 22, 2021"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0026","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1097\/01.ccm.0000084806.15352.da","article-title":"Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients","volume":"31","author":"de Wildt","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0027","first-page":"14","article-title":"First-pass metabolism of midazolam by the human intestine","volume":"60","author":"Paine","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0028","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40261-022-01156-4","article-title":"A phase 1, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects","volume":"42","author":"Darwish","year":"2022","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0029","series-title":"Presented at: American Society for Clinical Pharmacology & Therapeutics Annual Meeting","article-title":"Weight-Based Banded Dosing to Achieve Target Exposure and Exposure-Response Efficacy Analyses to Support Trofinetide Treatment in Rett Syndrome [poster]","author":"Darwish","year":"2023"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-409X(96)00009-9","article-title":"Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption","volume":"19","author":"Yu","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.clinthera.2023.12.007_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40261-023-01322-2","article-title":"Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects","volume":"44","author":"Darwish","year":"2024","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","article-title":"A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome","volume":"76","author":"Glaze","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0033","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1172\/JCI119439","article-title":"Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression","volume":"99","author":"Lown","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0034","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.tips.2011.08.005","article-title":"Cytochrome P450 enzymes in the brain: emerging evidence of biological significance","volume":"32","author":"Ferguson","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1528-1167.2010.02956.x","article-title":"Cellular localization and functional significance of CYP3A4 in the human epileptic brain","volume":"52","author":"Ghosh","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0037","first-page":"899","article-title":"Expression of cytochromes P450 in human breast tissue and tumors","volume":"24","author":"Huang","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0038","first-page":"135","article-title":"Is the role of the small intestine in first-pass metabolism overemphasized?","volume":"51","author":"Lin","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0039","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2133\/dmpk.25.28","article-title":"Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions","volume":"25","author":"Galetin","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK Models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin","volume":"7","author":"Hanke","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2020-000731","article-title":"Multisystem comorbidities in classic Rett syndrome: a scoping review","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr Open"},{"key":"10.1016\/j.clinthera.2023.12.007_bib0042","unstructured":"US Food and Drug Administration. Clinical Drug Interaction Studies\u2014Study Design, Data Analysis, and Clinical Implications Guidance for Industry [FDA website]. Available at: https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm292362.pdf. Accessed October 22, 2021."},{"key":"10.1016\/j.clinthera.2023.12.007_bib0043","unstructured":"European Medicines Agency. Guideline on the Investigation of Drug Interactions [EMA website]. Available at: https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-drug-interactions_en.pdf. Accessed October 22, 2021."},{"key":"10.1016\/j.clinthera.2023.12.007_bib0044","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration's Office of Clinical Pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J Pharm Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T17:17:10Z","timestamp":1729185430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0149291824000018"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}